Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib
- 11 July 2013
- journal article
- letter
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 369 (2), 197-198
- https://doi.org/10.1056/nejmc1302135
Abstract
Ruxolitinib, an inhibitor of Janus kinases (JAKs) 1 and 2, has been approved in the United States and Europe for the treatment of myelofibrosis.1 We report a case of progressive multifocal leukoencephalopathy (PML) in a patient with myelofibrosis after initiation of ruxolitinib therapy.Keywords
This publication has 4 references indexed in Scilit:
- JAKs and STATs in Immunity, Immunodeficiency, and CancerThe New England Journal of Medicine, 2013
- Risk of Natalizumab-Associated Progressive Multifocal LeukoencephalopathyThe New England Journal of Medicine, 2012
- Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MSNeurology, 2012
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for MyelofibrosisThe New England Journal of Medicine, 2012